The record
| Class | growth hormone secretagogue |
|---|---|
| Also known as | GRF 1-29, GHRH 1-29, Geref |
| Chain length | - |
| Molecular weight | 3,358 Da |
| Half-life | 11-12 minutes |
| Route | SC |
| Studied for | Pediatric growth hormone deficiency; Adult GH deficiency (off-label); Anti-aging therapy; Body composition optimization |
| Research use | GH axis evaluation; Pituitary function testing; Age-related GH decline |
| What has been shown | Increases GH secretion; Improves IGF-1 levels; Diagnostic utility for GH deficiency |
| How it works | Synthetic 29-amino acid peptide corresponding to the amino-terminal segment of natural GHRH (44 aa). Binds to GHRH receptors on pituitary somatotroph cells to stimulate synthesis and pulsatile release of endogenous growth hormone. Maintains normal feedback loop unlike exogenous GH administration. |
| Patent status | expired |
| Regulatory status | withdrawn (US); compounding available |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Muscle Hypertrophy / Anabolic Signaling (affection, 56%)
- GH Pulsatility Environment (affection, 85%)
- Adult GH deficiency (illness, 100%)
- Anti-aging protocols (illness, 40%)
- Anti-aging therapy (illness, 100%)
- Body composition optimization (illness, 100%)
- Cognitive support (illness, 30%)
- Growth hormone deficiency (illness, 40%)
- HIV-associated lipodystrophy (illness, 30%)
- Metabolic syndrome (illness, 40%)
- Pediatric growth hormone deficiency (illness, 100%)
- Visceral adiposity reduction (illness, 30%)
- Muscle loss or weakness (symptom, 67%)